Loading…
Employees: 1,805
Size Standard Chemical & Pharmaceutical (1720.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $329M, the 618th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$55.30 on 6 Nov 2026.
Performance Over six months the shares fell 0.3%, against -23.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 2.9% over the last twelve months (peer median +4.6%); the operating margin is 20.5% (peer median -3.2%).
Valuation It trades at 1.8× enterprise value to sales against a peer median of 4.6× (3rd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -21 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.2 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$7.08B | NT$7.02B | NT$6.79B | NT$6.24B | NT$5.85B |
| Revenue growth | — | +3% | +9% | +7% | — |
| Gross profit | NT$2.91B | NT$2.80B | NT$2.89B | NT$2.65B | NT$2.42B |
| EBITDA | NT$1.89B | NT$1.80B | NT$1.80B | NT$1.61B | NT$1.42B |
| Net income | NT$1.03B | NT$928M | NT$881M | NT$835M | NT$815M |
| Free cash flow | NT$1.11B | NT$1.38B | NT$1.07B | NT$760M | -NT$48.5M |
| Capital expenditure | NT$466M | NT$508M | NT$609M | NT$634M | NT$1.20B |
| Total debt | NT$1.04B | NT$1.13B | NT$921M | NT$1.70B | NT$2.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1720.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.9% | -9.9% | 2nd highest of 20 |
| 6-month return | -0.3% | -23.3% | 3rd highest of 20 |
| Distance from 52-week high | -8.7% | -35.9% | highest of 20 |
| Revenue growth (TTM) | +2.9% | +4.6% | 10th highest of 19 |
| Operating margin | 20.5% | -3.2% | 2nd highest of 19 |
| EV / Sales | 1.8× | 4.6× | 3rd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -10.4% | 15.1% | 2nd least demanding of 12 |
| Growth delivered (Del g) | +10.3% | +0.5% | 2nd highest of 12 |
| Hurdle (Req g minus delivered) | -20.7 pp | +7.8 pp | 3rd least demanding of 12 |
| ROIC minus cost of capital | +6.2 pp | -9.5 pp | 2nd highest of 19 |
| EV / EBITDA | 6.7× | 15.3× | 2nd cheapest of 6 |
| Net debt / EBITDA | -0.7× | 2.2× | 3rd least indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | 1.8× | -10.4% | +10.3% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | 6.2× | n/a | n/a |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | 7.9× | 58.0% | -12.8% |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | 11.5× | 22.5% | +0.5% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | 2.3× | 15.1% | +7.3% |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | 5.9× | 28.5% | -6.4% |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 2.3× | 37.7% | -3.2% |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | 5.0× | 2.5% | -4.9% |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | 1,229.5× | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | 3.5× | n/a | n/a |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | 4.8× | n/a | n/a |
| Eikon Therapeutics EIKN | United States | $320M | -41% | n/a | n/a | n/a | n/a | n/a |
| GC Corp. 005250.KS | South Korea | $319M | -32% | +10% | 1% | 1.2× | 31.5% | +7.4% |
| Shandong Sito Bio-technology 300583.SZ | China | $318M | -26% | +19% | 6% | 2.5× | 2.7% | +2.3% |
| Zhejiang Shengda Bio-Pharm 603079.SS | China | $318M | -29% | -3% | 7% | 2.5× | 5.7% | -0.3% |
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -211% | 4.3× | n/a | n/a |
| Kitazato 368A.T | Japan | $317M | -9% | +9% | 52% | 3.1× | -16.7% | +5.4% |
| ASKA Pharmaceutical 4886.T | Japan | $342M | -31% | +11% | n/a | n/a | n/a | n/a |
| BioDlink International 1875.HK | Hong Kong | $342M | -29% | -51% | -31% | 4.9× | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $343M | -9% | +6% | -104% | 22.9× | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $315M | -23% | +3% | 7% | 1.7× | 5.5% | +62.1% |